INFU · InfuSystem Holdings, Inc. — research history
Complete research history. Every dossier, draft, kill, publish, and lesson the system has produced on INFU. Public so users can audit, AI can re-reference. Live price refreshes every 60s.
About INFU · InfuSystem Holdings, Inc.
InfuSystem Holdings, Inc., through its subsidiaries, provides infusion pumps and related products and services in the United States and Canada. It operates through two segments: Patient Services and Device Solutions. The company supplies electronic ambulatory infusion pumps and associated disposable supply kits to oncology, infusion, and hospital outpatient chemotherapy clinics for the treatment of various cancers, including colorectal cancer, pain management, and other disease states. It also sells and rents new and pre-owned pole-mounted and ambulatory infusion pumps, and other durable medical equipment; sells treatment-related consumables; and provides biomedical recertification, maintenance, and repair services for oncology practices, as well as other healthcare site settings comprising hospitals, home care and home infusion providers, skilled nursing and acute care facilities, pain centers, and others. In addition, the company offers local and field-based customer support, as well as operates pump service and repair centers. The company was incorporated in 2005 and is headquartered in Rochester Hills, Michigan.
Live Quote
HOLD (score +1) · 12-1 mom 58.8% · RSI 49 · below_both · -15.8% from high
Targets blend Wall Street consensus (4 analysts: low $12.00 / mean $14.88 / high $17.50) with chart-derived floors and ceilings.
1-Year Chart · RSI · MACD
Research Timeline
Newest first. Each entry shows what stage produced it, the verdict/decision, and the reasoning.
InfuSystem is a small-cap ($168M) healthcare DME services company with two segments (Patient Services: pump rental/billing for oncology clinics; Device Solutions: equipment sales/rental). The investigation triggered on 3 Form-4 open-market P purchases filed May 12 — CEO Carrie Lachance (3,000 shares over 2 days), CFO Barry Steele (7,000 shares in one day), and Director Paul Gendron (5,000 shares) all buying at ~$8.46–$8.88 on May 8/11 when the stock had collapsed from $10.70 to $8.35 (-22% YTD). Q1 2026 EPS of $0.05 beat estimates by +25%. Analyst consensus target is $14.875 vs. current ~$8.35 — a 77% upside gap. However, forward P/E of ~28.8x is rich for a small healthcare services company with thin operating margins (4.7%), and there are no named near-term catalysts beyond earnings on Aug 4.